KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Repligen (RGEN) Research & Development (2016 - 2025)

Repligen (RGEN) has disclosed Research & Development for 16 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 12.36% to $13.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $54.2 million, a 25.41% increase, with the full-year FY2025 number at $54.2 million, up 25.41% from a year prior.
  • Research & Development was $13.1 million for Q4 2025 at Repligen, down from $14.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $14.2 million in Q3 2025 to a low of $7.6 million in Q1 2021.
  • A 5-year average of $10.9 million and a median of $10.6 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 107.01% in 2021, then fell 8.2% in 2024.
  • Repligen's Research & Development stood at $9.1 million in 2021, then increased by 21.87% to $11.1 million in 2022, then decreased by 7.45% to $10.3 million in 2023, then increased by 13.53% to $11.7 million in 2024, then rose by 12.36% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for RGEN's Research & Development are $13.1 million (Q4 2025), $14.2 million (Q3 2025), and $14.0 million (Q2 2025).